Figure 1From: Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutionsProbability of overall survival (A) and the time to tumor progression (B). The median overall survival was 141Â days, and the survival rates at 6, 12, and 18Â months were 47%, 21%, and 11%, respectively. The median time to tumor progression was 90Â days.Back to article page